Halofuginone reduces the inflammatory responses of DSS-induced colitis through metabolic reprogramming.

Abstract excerpt

Hypoxia and inflammation have been identified as the hallmarks of colitis, intertwined with metabolism. Here, we report that halofuginone (HF), an antiparasitic drug, attenuates dextran sulfate sodium (DSS)-induced colitis in mice, as represented by attenuating the disease activity index, inhibiting colonic shortening, ameliorating colonic lesions and histological signs of damage, reducing colonic myeloperoxidase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-Inflammatory Agents, Non-Steroidal
• Share to Colitis